CA2271865C - Tablet composition - Google Patents
Tablet composition Download PDFInfo
- Publication number
- CA2271865C CA2271865C CA002271865A CA2271865A CA2271865C CA 2271865 C CA2271865 C CA 2271865C CA 002271865 A CA002271865 A CA 002271865A CA 2271865 A CA2271865 A CA 2271865A CA 2271865 C CA2271865 C CA 2271865C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- tablet composition
- hydroxypropyl cellulose
- composition according
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A tablet composition containing N-(trans-4-isopropylcyclohexane-carbonyl)-D-phenylalanine and a disintegrator is rapidly disintegrated in the stomach speedily after administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.
Description
,. _1_ TABLET COMPOSITION
The present invention relates to a tablet composition for controlling the blood sugar levels of diabetics.
It is known that N-(trans-4-isopropylcylohexanecarbonyl)-D-phenylalanine of the formula:
0 H (1) .~,,~
N
H COOH
C H, .
~.,w CHa to exhibits an excellent effect in respect of lowering the blood sugar level when it is taken orally, and is thus useful as a medicine for diabetes [Japanese Patent Publication for Opposition Purpose (hereinafter referred to as "J. R. KOKOKU") No. Hei 4-15221].
However, it was found that when the compound of formula (I) is taken orally before or after a meal for the purpose of preventing the blood sugar level after the meal from rising, the bioavailability of the compound is lowered.
It is, therefore, an object of the present invention to provide a tablet composition which can be rapidly absorbed without being influenced by the meals and without impairing the essential properties of the compound of formula (I) 2o contained therein, which lowers the blood sugar level and has only a short According to the present invention, there is provided a tablet composition for lowering blood sugar levels of diabetics, containing as active ingredient the compound of formula (I) and a disintegrator.
In a preferred embodiment, the tablet composition of the invention further includes a filler, preferably a filler containing lactose.
.. -2_ According to another preferred embodiment, the tablet composition of the invention further includes hydroxypropyl cellulose as a binder.
After administration, the tablet compositions according to the invention are rapidly disintegrated in the stomach and absorbed without being influenced by the meals, to prevent the blood sugar levels of diabetics after meals from rising.
In the accompanying drawings:
Fig. 1 is a graph showing the concentration of the compound of formula (I) in the blood plasma of patients fasting from food; and Fig. 2 is another graph showing the concentration of the compound of formula (I) in the blood plasma of patients, which was administered before meals.
The active compound in the tablet composition of the present invention is N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine of the above formula (I).
Processes for producing the compound of formula (I) are described in J. P.
KOKOKU
No. Hei 4-15221. This compound can be obtained by, for example, condensing 4-isopropylcyclohexaneca~boxylic acid with D-phenylalanine or an ester thereof by, for example, an active ester method. Processes for obtaining stable crystals of this compound are described in Japanese Patent Unexamined Published Application (hereinafter referred to as "J. P. KOKAI") No. Hei 5-208943. For example, the compound of formula (I) can be obtained by crystallizing from a mixed solvent of 2o ethanol, acetone or the like and water at a temperature of not lower than 10°C.
The amount of the compound of formula (I) is generally present in the tablet composition of the invention in an amount of 5 to 50 % by weight, preferably 10 to 40 by weight, and more preferably 20 to 30 % by weight, based on the total weight of the composition.
The disintegrator is preferably a low substituted hydroxypropyl cellulose. The latter is a hydroxypropyl ether of cellulose which can be obtained by etherifying only a part of hydroxyl groups of the pyranose ring of a cellulose with propylene oxide.
When the hydroxypropyl group content of dry low substituted hydroxypropyl cellulose is determined, it is generally between 5.0 and 16.0 % by weight (see 3o Japanese Pharmacopeia, 13th Revision, D-885 to D-888 and U. S.
Pharmacopeia, 23ra Revision, pages 2253 to 2254). Examples of the low substituted hydroxypropyl cellulose include low substituted hydroxypropyl cellulose L-HPC (LH-11, LH-20, LH-21, LH-22, LH-30, LH-31 and LH-32; products of Shin-Etsu Chemical Co., Ltd.).
The disintegrator is generally present in the tablet composition of the invention in an amount of 5 to 50 % by weight, preferably 5 to 40 by weight, more preferably 10 to 40 % by weight, and most preferably 20 to 40 by weight, based on the total weight of the composition.
Sodium carboxymethyl cellulose, calcium carboxymethyl cellulose or sodium croscarmellose sodium can also be used as disintegrator. Although corn starch, sodium carboxymethyl starch, crystalline cellulose or partly pregelatinized starch 1o having a low disintegrating property is not preferably used alone, the disintegrating property thereof is improved by combining each of them with low substituted hydroxypropyl cellulose.
The tablet composition of the present invention can further contain lactose, starch, crystalline cellulose, calcium monohydrogen phosphate, light anhydrous silicic acid, titanium oxide or magnesium aluminometasilicate as a filler, in addition to the above-described ingredients. Among these, lactose is preferred because it is compatible with the compound of formula (I). The amount of filler can constitute the balance in the tablet composition. It generally ranges from 10 to 90 % by weight, more preferably 20 to 80 % by weight and most preferably 30 to 60 % by weight, based on the total weight of the composition.
Further, it is desirable to incorporate 0.1 to 5 % by weight, preferably 0.5 to 2 by weight, of hydroxypropyl cellulose as a binder so as to facilitate the granulation in the manufacturing process. Hydroxypropyl cellulose used for this purpose is different from the above-described low substituted hydroxypropyl cellulose. The quantity of hydroxypropyl group in dry hydroxypropyl cellulose generally ranges from 53.4 to 77.5 % by weight (see the Japanese Pharmacopeia, 13t'' Revision, D-880 to D-885 and U. S. Pharmacopeia, 23rd Revision, page 2253). Such a hydroxypropyl cellulose is easily available as HPC-L, L (fine powder) or the like (products of Nippon Soda Co., Ltd.).
3o The tablet composition of the present invention can contain other additives usually incorporated into tablet compositions in addition to the above-described ingredients, as long as the effect of the present invention is not impaired.
These additives include fillers such as crystalline cellulose, calcium monohydrogen phosphate, starch, light anhydrous silicic acid, titanium oxide, magnesium aluminometasilicate and polyethylene glycol; disintegrators such as starch, crystalline cellulose, hydroxypropyl starch and partly pregelatinized starch; binders such as gelatin, acacia, ethyl cellulose and polyvinyl alcohol; lubricants such as stearic acid, magnesium stearate, calcium stearate, talc and hydrogenated oil; coating agents such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymers and polyvinyl acetate phthalate; colorants such as tar colorant and titanium oxide; corrigents such as citric 1o acid, adipic acid, ascorbic acid and menthol; and surfactants such as glycerol monostearate, polysorbates, sodium laurylsulfate and sucrose esters of fatty acids.
The tablet composition of the present invention can be prepared by an ordinary wet granulation method, wherein the above-described ingredients are thoroughly mixed and then granulated with water which may contain a lower alcohol such as ethanol or isopropanol, the granules thus obtained are dried and, if necessary, reduced in size and tableted with a tableting machine. The tablets thus obtained can be coated, if desired.
The following non-limiting Examples further illustrate the present invention.
Example 1 2o The ingredients shown in Table 1 were weighed and all the ingredients excluding magnesium stearate were mixed with a highshear mixer for 10 minutes.
Purified water in an amount (15 to 75 parts by weight) such that granules having a diameter of 100 to 500 ~m would be obtained was added thereto, and the resultant mixture was granulated with a highshear mixer for 10 minutes. The granules thus obtained were reduced in size with a mill and then dried. Magnesium stearate was added to the dry granules obtained, and the mixture thus obtained was blended with a V-shaped blender for 2 minutes and tableted to provide tablets having a diameter of 7 mm, thickness of 3 mm and weight of 100 mg. The disintegration time of the tablets thus obtained in water was determined according to a disintegration test of the 3o Japanese Pharmacopeia. L-HPC(LH-31) (a product of Shin-Etsu Chemical Co., Ltd.) having a hydroxypropyl group content of 10 to 12.9 % by weight and an average particle diameter of not larger than 30 pm was used as the low substituted hydroxypropyl cellulose. The results are shown in Table 1.
Table 1 Comparative Composition composition of invention Compound of 25 25 25 25 25 25 25 25 25 25 formula (I) Lactose 74 49 44 54 64 54 44 44 34 44 Corn starch 20 10 20 10 Na carboxy- 10 10 methyl starch Partly 10 10 Pregelatinized starch Crystalline 5 20 10 10 10 cellulose Low substituted 20 10 20 10 20 hydroxypropyl cellulose Magnesium 1 1 1 1 1 1 1 1 1 1 stearate Disintegration >30 >30 >30 >30 11 0.8 3.1 3.1 3.0 3.8 time min As is apparent from Table 1, the tablets prepared by using a low substituted hydroxypropyl cellulose as the disintegrator were disintegrated more rapidly than tablets prepared by using another disintegrator.
Example 2 250 g of the compound of formula (I), 530 g of lactose and 200 g of low 1o substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) having a hydroxypropyl group content of 10.0 to 13.0 % by weight and an average particle diameter of not larger than 30 pm were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
Comparative Example 1 250 g of the compound of formula (I), 440 g of lactose, 100 g of corn starch and 200 g of crystalline cellulose were thoroughly mixed with a highshear mixer. 3.0 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 360 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried.
10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the tablets obtained in Example
The present invention relates to a tablet composition for controlling the blood sugar levels of diabetics.
It is known that N-(trans-4-isopropylcylohexanecarbonyl)-D-phenylalanine of the formula:
0 H (1) .~,,~
N
H COOH
C H, .
~.,w CHa to exhibits an excellent effect in respect of lowering the blood sugar level when it is taken orally, and is thus useful as a medicine for diabetes [Japanese Patent Publication for Opposition Purpose (hereinafter referred to as "J. R. KOKOKU") No. Hei 4-15221].
However, it was found that when the compound of formula (I) is taken orally before or after a meal for the purpose of preventing the blood sugar level after the meal from rising, the bioavailability of the compound is lowered.
It is, therefore, an object of the present invention to provide a tablet composition which can be rapidly absorbed without being influenced by the meals and without impairing the essential properties of the compound of formula (I) 2o contained therein, which lowers the blood sugar level and has only a short According to the present invention, there is provided a tablet composition for lowering blood sugar levels of diabetics, containing as active ingredient the compound of formula (I) and a disintegrator.
In a preferred embodiment, the tablet composition of the invention further includes a filler, preferably a filler containing lactose.
.. -2_ According to another preferred embodiment, the tablet composition of the invention further includes hydroxypropyl cellulose as a binder.
After administration, the tablet compositions according to the invention are rapidly disintegrated in the stomach and absorbed without being influenced by the meals, to prevent the blood sugar levels of diabetics after meals from rising.
In the accompanying drawings:
Fig. 1 is a graph showing the concentration of the compound of formula (I) in the blood plasma of patients fasting from food; and Fig. 2 is another graph showing the concentration of the compound of formula (I) in the blood plasma of patients, which was administered before meals.
The active compound in the tablet composition of the present invention is N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine of the above formula (I).
Processes for producing the compound of formula (I) are described in J. P.
KOKOKU
No. Hei 4-15221. This compound can be obtained by, for example, condensing 4-isopropylcyclohexaneca~boxylic acid with D-phenylalanine or an ester thereof by, for example, an active ester method. Processes for obtaining stable crystals of this compound are described in Japanese Patent Unexamined Published Application (hereinafter referred to as "J. P. KOKAI") No. Hei 5-208943. For example, the compound of formula (I) can be obtained by crystallizing from a mixed solvent of 2o ethanol, acetone or the like and water at a temperature of not lower than 10°C.
The amount of the compound of formula (I) is generally present in the tablet composition of the invention in an amount of 5 to 50 % by weight, preferably 10 to 40 by weight, and more preferably 20 to 30 % by weight, based on the total weight of the composition.
The disintegrator is preferably a low substituted hydroxypropyl cellulose. The latter is a hydroxypropyl ether of cellulose which can be obtained by etherifying only a part of hydroxyl groups of the pyranose ring of a cellulose with propylene oxide.
When the hydroxypropyl group content of dry low substituted hydroxypropyl cellulose is determined, it is generally between 5.0 and 16.0 % by weight (see 3o Japanese Pharmacopeia, 13th Revision, D-885 to D-888 and U. S.
Pharmacopeia, 23ra Revision, pages 2253 to 2254). Examples of the low substituted hydroxypropyl cellulose include low substituted hydroxypropyl cellulose L-HPC (LH-11, LH-20, LH-21, LH-22, LH-30, LH-31 and LH-32; products of Shin-Etsu Chemical Co., Ltd.).
The disintegrator is generally present in the tablet composition of the invention in an amount of 5 to 50 % by weight, preferably 5 to 40 by weight, more preferably 10 to 40 % by weight, and most preferably 20 to 40 by weight, based on the total weight of the composition.
Sodium carboxymethyl cellulose, calcium carboxymethyl cellulose or sodium croscarmellose sodium can also be used as disintegrator. Although corn starch, sodium carboxymethyl starch, crystalline cellulose or partly pregelatinized starch 1o having a low disintegrating property is not preferably used alone, the disintegrating property thereof is improved by combining each of them with low substituted hydroxypropyl cellulose.
The tablet composition of the present invention can further contain lactose, starch, crystalline cellulose, calcium monohydrogen phosphate, light anhydrous silicic acid, titanium oxide or magnesium aluminometasilicate as a filler, in addition to the above-described ingredients. Among these, lactose is preferred because it is compatible with the compound of formula (I). The amount of filler can constitute the balance in the tablet composition. It generally ranges from 10 to 90 % by weight, more preferably 20 to 80 % by weight and most preferably 30 to 60 % by weight, based on the total weight of the composition.
Further, it is desirable to incorporate 0.1 to 5 % by weight, preferably 0.5 to 2 by weight, of hydroxypropyl cellulose as a binder so as to facilitate the granulation in the manufacturing process. Hydroxypropyl cellulose used for this purpose is different from the above-described low substituted hydroxypropyl cellulose. The quantity of hydroxypropyl group in dry hydroxypropyl cellulose generally ranges from 53.4 to 77.5 % by weight (see the Japanese Pharmacopeia, 13t'' Revision, D-880 to D-885 and U. S. Pharmacopeia, 23rd Revision, page 2253). Such a hydroxypropyl cellulose is easily available as HPC-L, L (fine powder) or the like (products of Nippon Soda Co., Ltd.).
3o The tablet composition of the present invention can contain other additives usually incorporated into tablet compositions in addition to the above-described ingredients, as long as the effect of the present invention is not impaired.
These additives include fillers such as crystalline cellulose, calcium monohydrogen phosphate, starch, light anhydrous silicic acid, titanium oxide, magnesium aluminometasilicate and polyethylene glycol; disintegrators such as starch, crystalline cellulose, hydroxypropyl starch and partly pregelatinized starch; binders such as gelatin, acacia, ethyl cellulose and polyvinyl alcohol; lubricants such as stearic acid, magnesium stearate, calcium stearate, talc and hydrogenated oil; coating agents such as hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose phthalate, polyvinylacetal diethylaminoacetate, aminoalkyl methacrylate copolymers and polyvinyl acetate phthalate; colorants such as tar colorant and titanium oxide; corrigents such as citric 1o acid, adipic acid, ascorbic acid and menthol; and surfactants such as glycerol monostearate, polysorbates, sodium laurylsulfate and sucrose esters of fatty acids.
The tablet composition of the present invention can be prepared by an ordinary wet granulation method, wherein the above-described ingredients are thoroughly mixed and then granulated with water which may contain a lower alcohol such as ethanol or isopropanol, the granules thus obtained are dried and, if necessary, reduced in size and tableted with a tableting machine. The tablets thus obtained can be coated, if desired.
The following non-limiting Examples further illustrate the present invention.
Example 1 2o The ingredients shown in Table 1 were weighed and all the ingredients excluding magnesium stearate were mixed with a highshear mixer for 10 minutes.
Purified water in an amount (15 to 75 parts by weight) such that granules having a diameter of 100 to 500 ~m would be obtained was added thereto, and the resultant mixture was granulated with a highshear mixer for 10 minutes. The granules thus obtained were reduced in size with a mill and then dried. Magnesium stearate was added to the dry granules obtained, and the mixture thus obtained was blended with a V-shaped blender for 2 minutes and tableted to provide tablets having a diameter of 7 mm, thickness of 3 mm and weight of 100 mg. The disintegration time of the tablets thus obtained in water was determined according to a disintegration test of the 3o Japanese Pharmacopeia. L-HPC(LH-31) (a product of Shin-Etsu Chemical Co., Ltd.) having a hydroxypropyl group content of 10 to 12.9 % by weight and an average particle diameter of not larger than 30 pm was used as the low substituted hydroxypropyl cellulose. The results are shown in Table 1.
Table 1 Comparative Composition composition of invention Compound of 25 25 25 25 25 25 25 25 25 25 formula (I) Lactose 74 49 44 54 64 54 44 44 34 44 Corn starch 20 10 20 10 Na carboxy- 10 10 methyl starch Partly 10 10 Pregelatinized starch Crystalline 5 20 10 10 10 cellulose Low substituted 20 10 20 10 20 hydroxypropyl cellulose Magnesium 1 1 1 1 1 1 1 1 1 1 stearate Disintegration >30 >30 >30 >30 11 0.8 3.1 3.1 3.0 3.8 time min As is apparent from Table 1, the tablets prepared by using a low substituted hydroxypropyl cellulose as the disintegrator were disintegrated more rapidly than tablets prepared by using another disintegrator.
Example 2 250 g of the compound of formula (I), 530 g of lactose and 200 g of low 1o substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) having a hydroxypropyl group content of 10.0 to 13.0 % by weight and an average particle diameter of not larger than 30 pm were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
Comparative Example 1 250 g of the compound of formula (I), 440 g of lactose, 100 g of corn starch and 200 g of crystalline cellulose were thoroughly mixed with a highshear mixer. 3.0 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 360 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried.
10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the tablets obtained in Example
2 and Comparative Example 1 was examined. As controls, No. 3 hard gelatin capsules each containing 30 mg of the compound of formula (I) and 70 mg of lactose were used. The tablets or capsules were orally administered to beagles (n=8), and foods were given five minutes after. Blood samples were taken 0, 15, 30, 45, 60, 90, 120, 180, 240, 360 and 480 minutes after the administration and the concentration of the compound of formula (I) in the blood plasma was determined by HPLC. The time 3o for attaining the maximum blood concentration (Tmax), the maximum blood concentration (Cmax) and the area under the curve of the blood concentration (AUC) were determined. For comparison, the same tests were repeated except that the tablets or capsules were administered to the fasting beagles. The results are shown in Table 2 and Figs. 1 and 2.
Table 2 Cmax Tmax AUC
(pg/ml) (min) (fig min/ml) Before 6.63.3 68~ 30 1218278 meal Tablets of Ex.2 Fasting 9.712.6 47~ 36 1635526 Before 3.510.9 131 96 10181200 meal Tablets of Comp.
Ex. l Fasting 7.513.3 64~ 41 14621542 Before 3.111.1 2261145 7381210 meal Capsules Fasting 9.52.3 38~ 36 14451453 (Average ~ standard deviation, n = 8 ) It is apparent from Table 2 and Fig. 1 that when the tablet composition of the present invention was administered to the fasting beagles, the absorption thereof was equivalent to or slightly superior to that of the tablet composition and capsules of Comparative Example 1. In contrast, when the tablet composition of the present invention was administered before meals on the assumption that it is practically used in that way, it was rapidly absorbed without being influenced by foods and it could inhibit the rise of the blood sugar level of diabetics after meals. When the tablet composition or capsules of Comparative Example 1 were used in Comparative Example l, the absorption of the compound of formula (I) was low and impractical.
_g_ Example 3 330 g of the compound of formula (I), 450 g of lactose and 200 g of a low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer.
The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 121 mg and 1o containing 40 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 4 125 g of the compound of formula (I), 655 g of lactose and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer.
The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 15 mg of the compound of formula (I). The tablets were spray-coated 3o with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example l, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 5 250 g of the compound of formula (I), 430 g of lactose, 100 g of crystalline cellulose and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of 1o Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer.
10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 570 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried.
g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
2o The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 6 250 g of the compound of formula (I), 320 g of lactose, 100 g of corn starch, 100 g of crystalline cellulose, 100 g of partly pregelatinized starch and 100 g of hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were 3o thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 450 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 100 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example l, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 7 250 g of the compound of formula (I), 430 g of lactose, 100 g of sodium carboxymethyl starch and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 640 g of purified water were added thereto and the mixture obtained was 2o granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I).
The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of 3o Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Table 2 Cmax Tmax AUC
(pg/ml) (min) (fig min/ml) Before 6.63.3 68~ 30 1218278 meal Tablets of Ex.2 Fasting 9.712.6 47~ 36 1635526 Before 3.510.9 131 96 10181200 meal Tablets of Comp.
Ex. l Fasting 7.513.3 64~ 41 14621542 Before 3.111.1 2261145 7381210 meal Capsules Fasting 9.52.3 38~ 36 14451453 (Average ~ standard deviation, n = 8 ) It is apparent from Table 2 and Fig. 1 that when the tablet composition of the present invention was administered to the fasting beagles, the absorption thereof was equivalent to or slightly superior to that of the tablet composition and capsules of Comparative Example 1. In contrast, when the tablet composition of the present invention was administered before meals on the assumption that it is practically used in that way, it was rapidly absorbed without being influenced by foods and it could inhibit the rise of the blood sugar level of diabetics after meals. When the tablet composition or capsules of Comparative Example 1 were used in Comparative Example l, the absorption of the compound of formula (I) was low and impractical.
_g_ Example 3 330 g of the compound of formula (I), 450 g of lactose and 200 g of a low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer.
The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 121 mg and 1o containing 40 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 4 125 g of the compound of formula (I), 655 g of lactose and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 500 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer.
The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 15 mg of the compound of formula (I). The tablets were spray-coated 3o with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example l, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 5 250 g of the compound of formula (I), 430 g of lactose, 100 g of crystalline cellulose and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of 1o Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer.
10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 570 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried.
g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
2o The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 6 250 g of the compound of formula (I), 320 g of lactose, 100 g of corn starch, 100 g of crystalline cellulose, 100 g of partly pregelatinized starch and 100 g of hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were 3o thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 450 g of purified water were added thereto and the mixture obtained was granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 100 mg and containing 30 mg of the compound of formula (I). The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example l, like the coated tablets of Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Example 7 250 g of the compound of formula (I), 430 g of lactose, 100 g of sodium carboxymethyl starch and 200 g of low substituted hydroxypropyl cellulose (LH-31; a product of Shin-Etsu Chemical Co., Ltd.) were thoroughly mixed with a highshear mixer. 10 g of hydroxypropyl cellulose (HPC-L; a product of Nippon Soda Co., Ltd.) dissolved in 640 g of purified water were added thereto and the mixture obtained was 2o granulated with a highshear mixer. The granules thus obtained were reduced in size and dried. 10 g of magnesium stearate were added to the powder and the mixture thus obtained was tableted to provide tablets having a diameter of 7 mm, thickness of 3.7 mm and weight of 120 mg and containing 30 mg of the compound of formula (I).
The tablets were spray-coated with a coating liquid comprising 8 g of hydroxypropylmethyl cellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of purified water to obtain the coated tablets.
The influence of food on the oral absorption of the coated tablets obtained as described above was examined. The coated tablets had an absorption superior to that of the tablets or capsules of Comparative Example 1, like the coated tablets of 3o Example 2, when they were administered during fasting or before meals. In particular, the coated tablets could inhibit the rise of the blood sugar level of diabetics after meals.
Claims (18)
1. A tablet composition for lowering blood sugar levels of diabetics, comprising as active ingredient N-(traps-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrator.
2. A tablet composition according to claim 1, wherein the disintegrator is a low substituted hydroxypropyl cellulose.
3. A tablet composition according to claim 1 or 2, wherein the N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine is present in an amount of 5 to 50 %
by weight, based on the total weight of the composition.
by weight, based on the total weight of the composition.
4. A tablet composition according to claim 1, wherein the low substituted hydroxypropyl cellulose contains 5.0 to 16.0 % by weight of hydroxypropyl group.
5. A tablet composition according to claim 1, 2 or 3, wherein the low substituted hydroxypropyl cellulose is present in an amount of 5 to 50 % by weight, based on the total weight of the composition.
6. A tablet composition according to claim 1, further including at least one filler.
7. A tablet composition according to claim 5, wherein the filler is lactose.
8. A tablet composition according to claim 1, further including hydroxypropyl cellulose.
9. A tablet composition according to claim 7, wherein the hydroxypropyl cellulose contains 53.4 to 77.5 % by weight of hydroxypropyl group.
10. A tablet composition according to claim 7 or 8, wherein the hydroxypropyl cellulose is present in an amount of 0.1 to 5 % by weight, based on the total weight of the composition.
11. A tablet composition for lowering blood sugar levels of diabetics, comprising 5 to 50 % by weight of N-(traps-4-isopropylcyclohexanecarbonyl)-D-phenylalanine, 5 to 40 % by weight of low substituted hydroxypropyl cellulose and 10 to 90 % by weight of a filler.
12. A tablet composition according to claim 10, wherein the low substituted hydroxypropyl cellulose contains 5.0 to 16.0 % by weight of hydroxypropyl group.
13. A tablet composition according to claim 10, wherein the filler is lactose.
14. A tablet composition according to claim 10, further including hydroxypropyl cellulose.
15. A tablet composition according to claim 13, wherein the hydroxypropyl cellulose contains 53.4 to 77.5 % by weight of hydroxypropyl group.
16. A tablet composition according to claim 13 or 14, wherein the hydroxypropyl cellulose is present in an amount of 0.1 to 5 % by weight, based on the total weight of the composition.
17. A tablet composition for lowering blood sugar levels of diabetics, comprising 5 to 50 % by weight of N-(trans-4--isopropylcyclohexanecarbonyl)-D-phenylalanine, 5 to 40 % by weight of low substituted hydroxypropyl cellulose having a hydroxypropyl group content of 5.0 to 16.0 % by weight, 10 to 90 % by weight of a filler and 0. 1 to 5 % by weight of hydroxypropyl cellulose having a hydroxypropyl group content of 53.4 to 77.5 % by weight.
18. A tablet composition according to claim 16, wherein the filler is lactose.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8-318541 | 1996-11-15 | ||
| JP31854196 | 1996-11-15 | ||
| PCT/JP1997/004152 WO1998022105A1 (en) | 1996-11-15 | 1997-11-14 | Tabletted preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2271865A1 CA2271865A1 (en) | 1998-05-28 |
| CA2271865C true CA2271865C (en) | 2003-10-14 |
Family
ID=18100283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002271865A Expired - Lifetime CA2271865C (en) | 1996-11-15 | 1997-11-14 | Tablet composition |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US6143323A (en) |
| EP (3) | EP0965339B1 (en) |
| JP (1) | JP4171091B2 (en) |
| KR (1) | KR100343062B1 (en) |
| CN (1) | CN1245158C (en) |
| AT (2) | ATE503472T1 (en) |
| AU (1) | AU718350B2 (en) |
| CA (1) | CA2271865C (en) |
| DE (2) | DE69735644T2 (en) |
| DK (1) | DK1586314T3 (en) |
| ES (2) | ES2257772T3 (en) |
| PT (2) | PT965339E (en) |
| TW (1) | TW492878B (en) |
| WO (1) | WO1998022105A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE503472T1 (en) * | 1996-11-15 | 2011-04-15 | Ajinomoto Kk | NATEGLINIDE TABLET PREPARATIONS |
| ES2559766T3 (en) | 1998-05-18 | 2016-02-15 | Takeda Pharmaceutical Company Limited | Disintegrable tablets in the mouth |
| WO2000006126A1 (en) * | 1998-07-28 | 2000-02-10 | Takeda Chemical Industries, Ltd. | Rapidly disintegrable solid preparation |
| JP2000119160A (en) * | 1998-10-06 | 2000-04-25 | Kanebo Ltd | Skin cosmetic |
| US6878749B2 (en) | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
| US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| CO5200844A1 (en) * | 1999-09-17 | 2002-09-27 | Novartis Ag | A COMBINATION THAT INCLUDES NATEGLINED AND WHEN AT LEAST ANOTHER ANTI-DIABETIC COMPOUND USED FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR OF A DISEASE OR CONDITION ASSOCIATED WITH DIBETES |
| CA2395993A1 (en) | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| CN1234414C (en) * | 2000-03-17 | 2006-01-04 | 味之素株式会社 | Medicament for diabetic complications and neurological disorders and application thereof |
| DK1334962T3 (en) * | 2000-10-18 | 2007-12-10 | Ajinomoto Kk | Methods for preparing acylphenylalanine |
| RU2273629C2 (en) * | 2000-10-18 | 2006-04-10 | Адзиномото Ко., Инк. | Methods for preparing nateglinide crystals |
| BR0114846A (en) | 2000-10-24 | 2004-02-25 | Ajinomoto Kk | Method for Producing Nateglinide Type B Crystals Substantially Free of Type H Crystals |
| BR0114896A (en) * | 2000-10-24 | 2003-08-12 | Ajinomoto Kk | Preparation containing nateglinide, and method for producing the same |
| AU2001296000A1 (en) * | 2000-10-24 | 2002-05-27 | Ajinomoto Co., Inc. | Nateglinide-containing hydrophilic drug preparations |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| JP2003252749A (en) * | 2002-03-04 | 2003-09-10 | Shin Etsu Chem Co Ltd | External base |
| US6830759B2 (en) | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| CN1247194C (en) * | 2002-08-27 | 2006-03-29 | 石药集团中奇制药技术（石家庄）有限公司 | Nagelinai clathrate compound |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
| JP4505859B2 (en) * | 2003-08-08 | 2010-07-21 | 味の素株式会社 | Nateglinide-containing preparation |
| WO2005016315A1 (en) * | 2003-08-14 | 2005-02-24 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler |
| KR20120064735A (en) * | 2004-04-01 | 2012-06-19 | 아지노모토 가부시키가이샤 | Nateglinide-containing preparation |
| WO2005117840A1 (en) * | 2004-05-31 | 2005-12-15 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b |
| WO2006013444A1 (en) * | 2004-07-28 | 2006-02-09 | Ranbaxy Laboratories Limited | Preparations of stable pharmaceutical compositions of nateglinide and processes for their preparation |
| CA2575484A1 (en) * | 2004-08-04 | 2006-02-16 | Alza Corporation | Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition |
| EP1795207A1 (en) * | 2004-10-01 | 2007-06-13 | Nippon Zoki Pharmaceutical Co. Ltd. | Solid pharmaceutical preparation |
| US7276198B2 (en) * | 2004-12-28 | 2007-10-02 | The Goodyear Tire & Rubber Company | Method and mold for making tire with tie bar |
| WO2006080524A1 (en) * | 2005-01-31 | 2006-08-03 | Ajinomoto Co., Inc. | Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent |
| KR101506043B1 (en) * | 2006-12-07 | 2015-03-25 | 다이이찌 산쿄 가부시키가이샤 | Pharmaceutical composition containing low-substituted hydroxypropylcellulose |
| CA2672154C (en) * | 2006-12-07 | 2014-11-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition having improved storage stability |
| JP5289975B2 (en) * | 2006-12-07 | 2013-09-11 | 第一三共株式会社 | Solid preparation containing mannitol or lactose |
| CA2672157C (en) * | 2006-12-07 | 2016-07-26 | Daiichi Sankyo Company, Limited | Method for producing solid preparation |
| TWI405574B (en) * | 2007-06-21 | 2013-08-21 | Otsuka Pharma Co Ltd | Pharmaceutical solid preparation and production method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6354321A (en) * | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | Blood sugar lowering agent |
| JP3586471B2 (en) * | 1991-06-25 | 2004-11-10 | 三菱ウェルファーマ株式会社 | Torasemide-containing pharmaceutical composition |
| ATE149483T1 (en) | 1991-07-30 | 1997-03-15 | Ajinomoto Kk | CRYSTALS OF N-(TRANS-4- ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE AND METHOD FOR THE PRODUCTION THEREOF |
| CA2123677A1 (en) * | 1991-11-26 | 1993-06-10 | Issac Ghebre-Sellassie | Process and composition for the development of controlled release gemfibrozil dosage form |
| ATE503472T1 (en) * | 1996-11-15 | 2011-04-15 | Ajinomoto Kk | NATEGLINIDE TABLET PREPARATIONS |
-
1997
- 1997-11-14 AT AT05014497T patent/ATE503472T1/en active
- 1997-11-14 DE DE69735644T patent/DE69735644T2/en not_active Expired - Lifetime
- 1997-11-14 CA CA002271865A patent/CA2271865C/en not_active Expired - Lifetime
- 1997-11-14 TW TW086117009A patent/TW492878B/en not_active IP Right Cessation
- 1997-11-14 PT PT97912459T patent/PT965339E/en unknown
- 1997-11-14 JP JP32974597A patent/JP4171091B2/en not_active Expired - Lifetime
- 1997-11-14 ES ES97912459T patent/ES2257772T3/en not_active Expired - Lifetime
- 1997-11-14 PT PT05014497T patent/PT1586314E/en unknown
- 1997-11-14 AT AT97912459T patent/ATE322260T1/en not_active IP Right Cessation
- 1997-11-14 CN CNB971811407A patent/CN1245158C/en not_active Expired - Lifetime
- 1997-11-14 AU AU49654/97A patent/AU718350B2/en not_active Ceased
- 1997-11-14 DE DE69740161T patent/DE69740161D1/en not_active Expired - Lifetime
- 1997-11-14 EP EP97912459A patent/EP0965339B1/en not_active Expired - Lifetime
- 1997-11-14 WO PCT/JP1997/004152 patent/WO1998022105A1/en not_active Ceased
- 1997-11-14 EP EP05014497A patent/EP1586314B1/en not_active Expired - Lifetime
- 1997-11-14 DK DK05014497.1T patent/DK1586314T3/en active
- 1997-11-14 EP EP10010714A patent/EP2277517A1/en not_active Withdrawn
- 1997-11-14 ES ES05014497T patent/ES2364145T3/en not_active Expired - Lifetime
- 1997-11-14 KR KR1019997004308A patent/KR100343062B1/en not_active Expired - Lifetime
-
1999
- 1999-05-14 US US09/311,060 patent/US6143323A/en not_active Expired - Lifetime
-
2000
- 2000-09-29 US US09/672,896 patent/US6296872B1/en not_active Expired - Lifetime
-
2001
- 2001-08-03 US US09/920,830 patent/US6641841B2/en not_active Expired - Lifetime
-
2003
- 2003-02-05 US US10/358,324 patent/US6844008B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4171091B2 (en) | 2008-10-22 |
| WO1998022105A1 (en) | 1998-05-28 |
| ES2257772T3 (en) | 2006-08-01 |
| US20020028239A1 (en) | 2002-03-07 |
| EP0965339A4 (en) | 2003-04-23 |
| PT965339E (en) | 2006-06-30 |
| AU718350B2 (en) | 2000-04-13 |
| EP2277517A1 (en) | 2011-01-26 |
| ES2364145T3 (en) | 2011-08-25 |
| DE69740161D1 (en) | 2011-05-12 |
| DE69735644T2 (en) | 2007-05-03 |
| KR100343062B1 (en) | 2002-07-02 |
| US20030147951A1 (en) | 2003-08-07 |
| CA2271865A1 (en) | 1998-05-28 |
| US6296872B1 (en) | 2001-10-02 |
| US6844008B2 (en) | 2005-01-18 |
| US6143323A (en) | 2000-11-07 |
| US6641841B2 (en) | 2003-11-04 |
| CN1242704A (en) | 2000-01-26 |
| EP1586314A1 (en) | 2005-10-19 |
| KR20000053312A (en) | 2000-08-25 |
| PT1586314E (en) | 2011-07-01 |
| AU4965497A (en) | 1998-06-10 |
| EP0965339A1 (en) | 1999-12-22 |
| EP1586314B1 (en) | 2011-03-30 |
| EP0965339B1 (en) | 2006-04-05 |
| DE69735644D1 (en) | 2006-05-18 |
| ATE503472T1 (en) | 2011-04-15 |
| DK1586314T3 (en) | 2011-06-20 |
| JPH10194969A (en) | 1998-07-28 |
| ATE322260T1 (en) | 2006-04-15 |
| TW492878B (en) | 2002-07-01 |
| CN1245158C (en) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2271865C (en) | Tablet composition | |
| RU2142790C1 (en) | Pharmaceutical composition stabilized by basic agent | |
| AU597471B2 (en) | Stabilized ace inhibitor compositions | |
| US5151433A (en) | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations | |
| AU2001240092B2 (en) | Sustained release ranolazine formulations | |
| US6153223A (en) | Stabilized pharmaceutical compositions | |
| RU2384332C2 (en) | Prolonged release pharmaceutical preparative forms | |
| US6555551B1 (en) | Stable formulations of ACE inhibitors, and methods for preparation thereof | |
| IL141892A (en) | Sustained release ranolazine formulations | |
| US5037658A (en) | Direct dry compressible acetaminophen composition | |
| EP1030664A1 (en) | Pharmaceutical compositions containing zafirlukast | |
| KR100594606B1 (en) | Immediate release oral pharmaceutical composition | |
| IE883032L (en) | Pharmaceutical compositions comprising a piperidinoalkanol | |
| CN1762354A (en) | A stable pharmaceutical composition containing a calcium blocker | |
| US6764694B1 (en) | Stable formulations of ACE inhibitors, and methods for preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20171114 |